摘要
复发转移性胃肠间质瘤（GIST）的处理是目前临床治疗的一大难题。国际上一些大型临床试验显示．伊马替尼治疗可显著改善复发转移GIST患者的生存期。而手术联合伊马替尼已成为转移GIST的理想治疗方法。然而．两者如何联合应用尚存在争议。伊马替尼可能影响凝血机制．因此，建议术前1周停药。细胞减灭术在复发转移性GIST中有一定的临床疗效，可与靶向药物联合应用。而复发转移GIST的临床试验尚需进一步评价。
Currently, the treatment of recurrent or metastatic gastrointestinal stromal tumor （GIST） has become a tremendous challenge. Some international clinical trials revealed that imatinib might significantly improve the survival of patients with recurrent or metastatic GIST. Though the combination of surgery and imatinib has become an ideal treatment of metastatic GIST, there still exist some controversies regarding how to combine the two methods. Imatinib may influence the blood coagulation mechanism, therefore it is suggested that imatinib cessation should be performed a week before operation. Cytoreduetive surgery has some clinical effects on recurrent or metastatic GIST, which can be combined with targeted therapy. Furthermore, the clinical trial for recurrent or metastatic GIST needs further evaluation.
出处
《中华胃肠外科杂志》
CAS
2012年第3期225-227,共3页
Chinese Journal of Gastrointestinal Surgery
关键词
胃肠间质瘤
复发
转移
伊马替尼
外科手术
Gastrointestinalstromal tumors
Recurrence
Metastasis
Imatinib
Surgical procedures
